CVRx shares rose 11.6% to close at $5.86, driven by investor optimism following strong first-quarter 2026 results. The medical device company posted a loss of 50 cents per share on revenues of $14.8 million, with both figures exceeding Zacks Consensus Estimates. For the upcoming quarter, CVRx is expected to report a loss of $0.52 per share on revenues of $15.64 million, representing year-over-year improvements of 8.8% and 15.1%, respectively. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank of Hold. CVRx is part of the medical instruments industry, alongside companies like Steris, which gained 2.4% in the last session.

CVRx to present at the William Blair 46th Annual Growth Stock Conference. GlobeNewswire | CVRx, Inc. Today at 1:30pm PDT MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim(TM) is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike Vallie ICR Healthcare 443-213-0501 [email protected] Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.